Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125523433 | 12552343 | 3 | F | 20160702 | 20160729 | 20160713 | 20160805 | EXP | JP-GLAXOSMITHKLINE-JP2016JPN096024 | GLAXOSMITHKLINE | 62.89 | YR | M | Y | 64.00000 | KG | 20160805 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125523433 | 12552343 | 1 | PS | VALTREX | VALACYCLOVIR HYDROCHLORIDE | 1 | Oral | 500 MG, QD | 1000 | MG | Y | 20487 | 500 | MG | TABLET | QD | |||
| 125523433 | 12552343 | 2 | C | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Oral | 75 MG, BID | U | 0 | 75 | MG | TABLET | BID | |||||
| 125523433 | 12552343 | 3 | C | Zyloric | ALLOPURINOL | 1 | Oral | 100 MG, QD | U | 0 | 100 | MG | TABLET | QD | |||||
| 125523433 | 12552343 | 4 | C | Dermovate | CLOBETASOL | 1 | Cutaneous | U | 0 | OINTMENT | |||||||||
| 125523433 | 12552343 | 5 | C | RENIVACE | ENALAPRIL | 1 | Oral | 5 MG, QD | U | 0 | 5 | MG | QD | ||||||
| 125523433 | 12552343 | 6 | C | ALFACALCIDOL | ALFACALCIDOL | 1 | Oral | 0.5 ?G, QD | U | 0 | .5 | UG | QD | ||||||
| 125523433 | 12552343 | 7 | C | MANICALOT | MANIDIPINE HYDROCHLORIDE | 1 | Oral | 10 MG, QD | U | 0 | 10 | MG | QD | ||||||
| 125523433 | 12552343 | 8 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 40 MG, BID | U | 0 | 40 | MG | BID | ||||||
| 125523433 | 12552343 | 9 | C | RENAGEL | SEVELAMER HYDROCHLORIDE | 1 | Oral | 250 MG, TID | U | 0 | 250 | MG | TID | ||||||
| 125523433 | 12552343 | 10 | C | BAYASPIRIN | ASPIRIN | 1 | Oral | 100 MG, QD | U | 0 | 100 | MG | QD | ||||||
| 125523433 | 12552343 | 11 | C | FOSRENOL | LANTHANUM CARBONATE | 1 | Oral | 250 MG, TID | U | 0 | 250 | MG | TID | ||||||
| 125523433 | 12552343 | 12 | C | ARTIST | CARVEDILOL | 1 | Oral | 2.5 MG, TID | U | 0 | 2.5 | MG | TID | ||||||
| 125523433 | 12552343 | 13 | C | LEVOFLOXACIN HEMIHYDRATE | LEVOFLOXACIN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125523433 | 12552343 | 1 | Herpes zoster |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125523433 | 12552343 | OT |
| 125523433 | 12552343 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125523433 | 12552343 | Abnormal behaviour | |
| 125523433 | 12552343 | Agitation | |
| 125523433 | 12552343 | Altered state of consciousness | |
| 125523433 | 12552343 | Dysarthria | |
| 125523433 | 12552343 | Euphoric mood | |
| 125523433 | 12552343 | Memory impairment | |
| 125523433 | 12552343 | Psychiatric symptom |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125523433 | 12552343 | 1 | 20160630 | 20160704 | 0 |